Immunotherapy in non-small cell lung cancer:rationale,recent advances and future perspectives
作者机构：Department of Respiratory and Critical Care MedicineWest China HospitalSichuan UniversityChengdu 610041China Precision Medicine Research CenterWest China HospitalSichuan UniversityChengdu 610041China Clinical Medical College and the First Affiliated Hospital of Chengdu Medical CollegeChengdu 610500China Department of Clinical Research ManagementWest China HospitalSichuan UniversityChengdu 610041China
出 版 物：《Precision Clinical Medicine》 (精准临床医学（英文）)
年 卷 期：2021年第4卷第4期
页 面：258-270页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：This study was supported by the National Natural Science Foundation of China to Wemin Li(Grants No.81871890 and 91859203) the Science and Technology Support Program of Sichuan Province to Yalun Li(Grant No.2020YFS0572)
主 题：non-small cell lung cancer immunotherapy immune checkpoint inhibitors adoptive cell therapy vaccine
摘 要：Lung cancer,with non-small cell lung cancer(NSCLC)being the major type,is the second most commonmalignancy and the leading cause of cancer-related death ***,represented by immune checkpoint inhibitors(ICIs),has been one of the greatest advances in recent years for the treatment of solid tumors including ***,not all NSCLC patients experience an effective response to immunotherapy with the established selection criteria of programmed death ligand 1(PD-L1)and tumor mutational burden(TMB).Furthermore,a considerable proportion of patients experience unconventional responses,including pseudoprogression or hyperprogressive disease(HPD),immune-related toxicities,and primary or acquired resistance during the immunotherapy *** better understand the immune response in NSCLC and provide reference for clinical decision-making,we herein review the rationale and recent advances in using immunotherapy to treat ***,we discuss the current challenges and future strategies of this approach to improve its efficacy and safety in treating NSCLC.
维普期刊数据库